Pacific Biosciences of California(US:PACB) ZACKSยท2025-07-10 23:16Company Performance - Pacific Biosciences of California (PACB) closed at $1.50, with a daily increase of +1.35%, outperforming the S&P 500's gain of 0.28% [1] - The stock has increased by 27.59% over the past month, leading the Medical sector's gain of 0.24% and the S&P 500's gain of 4.37% [1] Earnings Expectations - Analysts expect Pacific Biosciences to report earnings of -$0.18 per share, reflecting a year-over-year growth of 10% [2] - The revenue forecast for the upcoming quarter is $36.46 million, indicating a growth of 1.26% compared to the same quarter last year [2] Full Year Projections - For the full year, earnings are projected at -$0.64 per share and revenue at $155.12 million, showing changes of +22.89% and +0.72% respectively from the previous year [3] Analyst Sentiment - Recent adjustments to analyst estimates indicate positive sentiment towards Pacific Biosciences' business operations and profit generation capabilities [4] - The Zacks Rank system, which assesses stock performance based on estimate changes, currently ranks Pacific Biosciences as 1 (Strong Buy) [6] Industry Context - The Medical - Instruments industry, which includes Pacific Biosciences, has a Zacks Industry Rank of 173, placing it in the bottom 30% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]